NRXP NRX Pharmaceuticals Inc
Price (delayed)
$1.79
Market cap
$30.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.36
Enterprise value
$35.41M
Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination
Highlights
NRX Pharmaceuticals's debt has decreased by 28% YoY
NRXP's EPS is up by 41% year-on-year but it is down by 10% since the previous quarter
NRX Pharmaceuticals's net income has decreased by 23% from the previous quarter but it has increased by 17% YoY
The company's equity has shrunk by 98% YoY and by 23% QoQ
NRX Pharmaceuticals's quick ratio has plunged by 71% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of NRXP
Market
Valuations
Earnings
Shares outstanding
16.92M
Market cap
$30.28M
Enterprise value
$35.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$18.5M
Net income
-$25.13M
EBIT
-$24.9M
EBITDA
-$24.89M
Free cash flow
-$10.64M
Per share
Balance sheet
Liquidity
EPS
-$2.36
EPS diluted
-$2.36
Free cash flow per share
-$1
Book value per share
-$1.92
Revenue per share
$0
TBVPS
$0.34
Total assets
$3.65M
Total liabilities
$26.87M
Debt
$6.58M
Equity
-$23.22M
Working capital
-$18.56M
Debt to equity
-0.28
Current ratio
0.15
Quick ratio
0.07
Net debt/EBITDA
-0.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-585.5%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NRXP stock price
How has the NRX Pharmaceuticals stock price performed over time
Intraday
-4.28%
1 week
-11.82%
1 month
-15.57%
1 year
-65.58%
YTD
-18.64%
QTD
-12.68%
Financial performance
How have NRX Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$18.5M
Net income
-$25.13M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 34% YoY and by 10% from the previous quarter
NRX Pharmaceuticals's net income has decreased by 23% from the previous quarter but it has increased by 17% YoY
Growth
What is NRX Pharmaceuticals's growth rate over time
Valuation
What is NRX Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NRXP's EPS is up by 41% year-on-year but it is down by 10% since the previous quarter
The company's equity has shrunk by 98% YoY and by 23% QoQ
Efficiency
How efficient is NRX Pharmaceuticals business performance
NRX Pharmaceuticals's ROA has decreased by 50% from the previous quarter
Dividends
What is NRXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NRXP.
Financial health
How did NRX Pharmaceuticals financials performed over time
The total assets is 86% less than the total liabilities
NRX Pharmaceuticals's quick ratio has plunged by 71% YoY and by 13% from the previous quarter
NRX Pharmaceuticals's current ratio has plunged by 58% YoY and by 25% from the previous quarter
NRX Pharmaceuticals's debt is 128% more than its equity
The company's equity has shrunk by 98% YoY and by 23% QoQ
The debt to equity has soared by 64% YoY and by 20% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.